Single Arm Phase I Trail of Autologous Tumor Infiltrating Lymphocyte Injection (GT202) in the Treatment of Metastatic or Recurrent Gynecological Tumors
A prospective, open-label, non-randomized, Phase 1 study evaluating autologous tumor infiltrating lymphocyte injection (GT202) in the treatment of metastatic or recurrent Gynecological tumors.
Metastatic or Recurrent Gynecological Tumors
BIOLOGICAL: Autologous Tumor Infiltrating Lymphocyte Injection (GT202)
Types and incidence of Dose-limiting toxicity (DLT), Dose-limiting toxicity (DLT) will be collected and graded according to CTCAE v5.0, up to 28 days after GT202 infusion|Types and incidence of adverse events (AEs) ï¼Œserious adverse events (SAEs) and adverse events of special interest (AESI), AE will be collected and graded according to CTCAE v5.0, Up to 2 years after GT202 infusion|Maximum tolerated dose, Evaluate the Maximum tolerated dose of GT202 in Metastatic or Recurrent Gynecological Tumors patients, up to 28 days after GT202 infusion
Overall response rate (ORR), ORR will be calculated as the percentage of patients who achieved partial response (PR) or better., up to 6 weeks, 12 weeks, 18 weeks, 24 weeks after GT202 infusion|Duration of Response (DOR), Time from first response to disease progression or death from any cause, Up to 2 years after GT202 infusion|Progression-free Survival (PFS), PFS will be calculated as the time from GT202 infusion to disease progression or death from any cause (whichever occurs first)., Up to 2 years after GT202 infusion|Overall Survival (OS), Time from GT202 infusion to time of death due to any cause, Up to 2 years after GT202 infusion|Disease Control Rate (DCR), DCR will be calculated as the percentage of patients who achieved Stable Disease(SD) or better., up to 6 weeks, 12 weeks, 18 weeks, 24 weeks after GT202 infusion
A prospective, open-label, non-randomized, Phase 1 study evaluating autologous tumor infiltrating lymphocyte injection (GT202) in the treatment of metastatic or recurrent Gynecological tumors.